AT496624T
A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
Abstract
A for treating osteonecrosis and/or exfoliative osteonecrosis double phosphonate. The medicine is further can be used for preventing osteonecrosis and/or exfoliative osteonecrosis and a any complication the outbreak of two diseases are connected.
Term
Term ended
Expired 13 December 2021, 4.8 years ago.
- Priority
- Filed
- Granted
- Expired
- Today
46 members in 25 offices
Priority claims4
| Document | Office | Kind | Date |
|---|---|---|---|
| PR290701 | Australia | A | |
| PR418701 | Australia | A | |
| PR665401 | Australia | A | |
| 0101616 | Australia | W |
Members46
| Document | Office | Kind | |
|---|---|---|---|
| CA2435552A1 | Canada | A1 | |
| WO02062351A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO02080933A1 | World Intellectual Property Organization (WIPO) | A1 | |
| NO20033446D0 | Norway | D0 | |
| KR20030072399A | Republic of Korea | A | |
| NO20033446L | Norway | L | |
| EP1365769A1 | European Patent Office (EPO) | A1 | |
| HU0303013A2 | Hungary | A2 | |
| HUP0303013A2 | Hungary | A2 | |
| BR0116862A | Brazil | A | |
| EP1383509A1 | European Patent Office (EPO) | A1 | |
| SK9862003A3 | Slovakia | A3 | |
| US2004097469A1 | United States of America | A1 | |
| CZ20032408A3 | Czechia | A3 | |
| US2004157798A1 | United States of America | A1 | |
| JP2004526747A | Japan | A | |
| JP2004527479A | Japan | A | |
| CN1529604A | China | A | |
| PL361909A1 | Poland | A1 | |
| HK1061797A | Hong Kong, China | A | |
| MXPA03007029A | Mexico | A | |
| ZA200305890B | South Africa | B | |
| NZ527351A | New Zealand | A | |
| NZ528659A | New Zealand | A | |
| RU2003127076A | Russian Federation | A | |
| EP1365769A4 | European Patent Office (EPO) | A4 | |
| EP1383509A4 | European Patent Office (EPO) | A4 | |
| CN1233325C | China | C | |
| AU2002221339B2 | Australia | B2 | |
| RU2284821C2 | Russian Federation | C2 | |
| AU2002244520B2 | Australia | B2 | |
| HU0303013A3 | Hungary | A3 | |
| HUP0303013A3 | Hungary | A3 | |
| US7425549B2 | United States of America | B2 | |
| US2009005347A1 | United States of America | A1 | |
| US7612050B2 | United States of America | B2 | |
| CZ301361B6 | Czechia | B6 | |
| CA2435552C | Canada | C | |
| IL157201A | Israel | A | |
| EP1365769B1 | European Patent Office (EPO) | B1 | |
| AT496624TThis record | Austria | T | |
| ATE496624T1 | Austria | T1 | |
| DE60143964D1 | Germany | D1 | |
| DK1365769T3 | Denmark | T3 | |
| ES2362024T3 | Spain | T3 | |
| SI1365769T1 | Slovenia | T1 |
1 legal event, as the office reported them to INPADOC
Events
| Event | Code | |
|---|---|---|
| Publication of translation of european patent specificationUEP | UEP |
Numbers
- Application
- 1273650
Titles2
- German
- ARZNEIMITTEL ZUR BEHANDLUNG VON OSTEONEKROSE UND ZUR VERSORGUNG VON PATIENTEN MIT RISIKO FÜR DIE ENTSTEHUNG VON OSTEONEKROSE
- English
- DRUGS TO TREAT OSTEONE COSMETICS AND TO SUPPLY PATIENTS WITH RISK TO OSTEONE CRYOSIS
Classification
- CPC, 19
- A61K31/663
- A61K31/198
- A61K31/675
- A61K35/28
- A61K38/1825
- A61K38/1841
- A61K38/1875
- A61K38/30
- A61K38/39
- A61L27/54
- A61L2300/252
- A61L2300/414
- A61L2430/02
- A61P19/00
- A61P19/02
- A61P19/08
- A61P29/00
- A61P41/00
- A61P43/00
- IPC, 13
- A61K31 198
- A61K31 663
- A61K31 675
- A61K35 28
- A61K38 18
- A61K38 22
- A61K38 30
- A61K38 39
- A61L27 54
- A61P19 08
- A61P29 00
- A61P41 00
- A61P43 00